Independent directory Public ClinicalTrials.gov records United States
ClinicalTrials.gov record
Completed Phase 3 Interventional Results available

A Study to Evaluate the Efficacy and Safety of Bimekizumab Compared to an Active Comparator in Adult Subjects With Moderate to Severe Chronic Plaque Psoriasis

ClinicalTrials.gov ID: NCT03536884

Public ClinicalTrials.gov record NCT03536884. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.

ClinicalTrials.gov public records Last synced May 19, 2026, 11:10 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official title

A Multicenter, Randomized, Double-Blind, Secukinumab-Controlled, Parallel-Group Study to Evaluate the Efficacy and Safety of Bimekizumab in Adult Subjects With Moderate to Severe Chronic Plaque Psoriasis

Study identification

NCT ID
NCT03536884
Recruitment status
Completed
Study type
Interventional
Phase
Phase 3
Lead sponsor
UCB Biopharma SRL
Industry
Enrollment
743 participants

Conditions and interventions

Interventions

  • Bimekizumab Drug
  • Placebo Other
  • Secukinumab Drug

Drug · Other

Eligibility (public fields only)

Age range
18 Years and older
Sex
All
Healthy volunteers
Healthy volunteers not accepted

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date
Jun 12, 2018
Primary completion
Sep 11, 2019
Completion
Aug 8, 2023
Last update posted
Apr 14, 2026

2018 – 2023

United States locations

U.S. sites
25
U.S. states
14
U.S. cities
23
Facility City State ZIP Site status
Ps0015 975 Santa Ana California 92701
Ps0015 939 Danbury Connecticut 06810
Ps0015 903 Ocala Florida 34470
Ps0015 921 Ormond Beach Florida 32174
Ps0015 977 Pembroke Pines Florida 33028
Ps0015 936 Tampa Florida 33613
Ps0015 976 Tampa Florida 33614
Ps0015 970 West Palm Beach Florida 33409
Ps0015 966 Sandy Springs Georgia 30328
Ps0015 954 Skokie Illinois 60077
Ps0015 972 West Dundee Illinois 60118
Ps0015 900 West Des Moines Iowa 50265
Ps0015 944 New Orleans Louisiana 70115
Ps0015 915 Clayton Missouri 63105
Ps0015 953 St Louis Missouri 63141
Ps0015 901 Portsmouth New Hampshire 03801
Ps0015 965 Kew Gardens New York 11415
Ps0015 969 High Point North Carolina 27262
Ps0015 971 Wilmington North Carolina 28405
Ps0015 980 Bexley Ohio 43209
Ps0015 920 Portland Oregon 97210
Ps0015 929 Portland Oregon 97223
Ps0015 979 Dallas Texas 75246
Ps0015 924 Houston Texas 77004
Ps0015 978 Pflugerville Texas 78660

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

Non-U.S. locations

This page focuses on the U.S. directory. The official record also lists 52 non-U.S. sites.

About this trial record page

What this page shows
Public field values for ClinicalTrials.gov record NCT03536884, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do
No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from
Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh
Last update posted Apr 14, 2026 · Synced May 19, 2026

Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.

Open the official record

The complete protocol, eligibility criteria, and contact information for NCT03536884 live on ClinicalTrials.gov.

View official ClinicalTrials.gov record →